Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) Shares Outstanding (Weighted Average) (2019 - 2025)

BioScience Health Innovations (BHIC) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 4.73% to $11.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Dec 2025, up 4.73% year-over-year, with the annual reading at $11.0 million for FY2025, 4.73% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $11.0 million at BioScience Health Innovations, roughly flat from $11.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $43.9 million in Q1 2025, with the low at $5.5 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $18.6 million, with a median of $10.7 million recorded in 2024.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 198.57% in 2024, while the deepest fall reached 74.05% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $5.5 million in 2021, then changed by 0.0% to $5.5 million in 2022, then skyrocketed by 518.23% to $33.8 million in 2023, then tumbled by 68.95% to $10.5 million in 2024, then increased by 4.73% to $11.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $11.0 million, $11.0 million, and $43.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.